Clinical Trial Results: A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rocatinlimab's effect on vaccine antibody response in adults with moderate-to-severe atopic dermatitis has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2026-07-23